1
|
Leroy M, Desmedt E, Deramoudt L, Vasseur M, Odou P, Béhal H, Décaudin B, Mortier L, Simon N. Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma. Melanoma Res 2024; 34:258-264. [PMID: 38489575 DOI: 10.1097/cmr.0000000000000965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2024]
Abstract
Nivolumab was first authorized at a weight-based dose (WBD) of 3 mg/kg every two weeks (Q2W). Since 2017, a fixed dose (FD) regimen [first 240 mg Q2W and then 480 mg per month (Q4W)] was allowed. The objective of the study was to compare a WBD regimen and an FD regimen with regard to effectiveness and safety. We conducted a single-center, retrospective, real-life study of consecutive adult patients who had received a WBD of nivolumab or an FD of 480 mg Q4W. The primary endpoint was the occurrence of grade ≥3 immune-related adverse events (irAEs). The secondary endpoints were overall survival and cost of the treatment. In all, 342 patients were included: 71 in the WBD cohort and 271 in the FD cohort. Of these patients, 201 patients (59.6%) experienced an irAE, and 24 of these events were graded as ≥3. At 12 months, there was no significant difference in irAE occurrence between the two cohorts [hazard ratio (95% confidence interval): 0.54 (0.21-1.36), P = 0.19]. The 12-month overall survival rate was significantly lower in the WBD cohort ( P < 0.001). Switching from a fortnightly weight dose to a fixed monthly dose halves the cost of hospitalization. Our results did not show a significant difference between WBD and FD cohort in the occurrence of severe irAEs. However overall survival appeared to be significantly higher in FD group. Some clinical trials are investigating a hybrid dosing regimen in which a WBD is capped by an FD. The present results need to be confirmed in prospective studies.
Collapse
Affiliation(s)
| | - Eve Desmedt
- Service de Dermatologie, Hôpital C. Huriez, CHU de Lille
| | - Laure Deramoudt
- Institut de Pharmacie, CHU Lille
- Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées
| | - Michèle Vasseur
- Institut de Pharmacie, CHU Lille
- Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées
| | - Pascal Odou
- Institut de Pharmacie, CHU Lille
- Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées
| | | | - Bertrand Décaudin
- Institut de Pharmacie, CHU Lille
- Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées
| | - Laurent Mortier
- Department of Dermatology, Claude Huriez Hospital, CARADERM and University of Lille, Lille, France
| | - Nicolas Simon
- Institut de Pharmacie, CHU Lille
- Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées
| |
Collapse
|
2
|
Boileau M, Dubois M, Pruvot C, Desmedt E, Templier C, Meyer N, Mirabel X, Mortier L. Sequential combination of Sonic Hedgehog inhibitors followed by consolidation radiotherapy in locally advanced basal cell carcinoma. Clin Exp Dermatol 2024:llae068. [PMID: 38440960 DOI: 10.1093/ced/llae068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 02/04/2024] [Accepted: 03/03/2024] [Indexed: 03/06/2024]
Abstract
BACKGROUND Sonic Hedgehog inhibitors (SHHis) are an effective treatment in locally advanced basal cell carcinoma (laBCC), but the use of these drugs is limited by adverse events and relapse at discontinuation in around half of patients. A few cases of patients treated concomitantly by radiotherapy (RT) and SHHis have been reported in the literature, suggesting that the combination results in an improved overall response. Maintaining complete response after stopping treatment is a concern, especially since resuming treatment in the case of relapse does not guarantee a new therapeutic response. The optimal combination and sequence of treatment to improve local control of laBCCs are not yet defined. OBJECTIVE We hypothesized that consolidation RT after complete response to SHHis could reduce the risk of relapse at discontinuation. METHODS We present a case series of patients with laBCCs who achieved complete response (CR) after SHHi treatment and were treated with consolidation RT. Patients were evaluated by a skin cancer board. The closure RT technique and dosage were refined by a radiotherapist. RESULTS Eleven patients were included. SHHis were prescribed for 5 months (range 4-11). Consolidation RT was performed after CR to SHHis and discontinuation. RT was delivered at a median dose of 45 Gy (range 40.5-66) in 10 fractions (range 9-33). With a median follow-up of 23 months, all patients maintained complete clinical response. This strategy was well tolerated with no grade 3 adverse events. CONCLUSION SHHi treatment followed by RT consolidation after drug discontinuation seems effective and safe. Further studies are needed to develop a precise strategy for the management of laBCCs.
Collapse
Affiliation(s)
- Marie Boileau
- Department of Dermatology, CHU Lille, F-59000, Lille, France
- Univ. Lille, Departement of Medecin, F59000, Lille, France
| | - Manon Dubois
- Department of Dermatology, CHU Lille, F-59000, Lille, France
- Univ. Lille, Departement of Medecin, F59000, Lille, France
| | - Clément Pruvot
- Department of Dermatology, CHU Lille, F-59000, Lille, France
- Univ. Lille, Departement of Medecin, F59000, Lille, France
| | - Eve Desmedt
- Department of Dermatology, CHU Lille, F-59000, Lille, France
| | - Carole Templier
- Department of Dermatology, CHU Lille, F-59000, Lille, France
| | - Nicolas Meyer
- Medical Office, Medipole Garonne, 31036, Toulouse, France
- CARADERM Network, University Hospital LILLE, 59000 France
| | - Xavier Mirabel
- Universitary Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France
- CARADERM Network, University Hospital LILLE, 59000 France
| | - Laurent Mortier
- Department of Dermatology, CHU Lille, F-59000, Lille, France
- Univ. Lille, Departement of Medecin, F59000, Lille, France
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
- CARADERM Network, University Hospital LILLE, 59000 France
| |
Collapse
|
3
|
Hober C, Jamme P, Desmedt E, Greliak A, Mortier L. Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab. Ther Adv Med Oncol 2021; 13:17588359211015493. [PMID: 34104225 PMCID: PMC8170330 DOI: 10.1177/17588359211015493] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Accepted: 04/09/2021] [Indexed: 11/29/2022] Open
Abstract
Cutaneous squamous cell carcinoma (cSCC) accounts for 20% of skin cancers. At an advanced stage the prognosis is poor, making cSCC the second leading cause of death from skin cancer. In cases of metastatic or unresectable disease, anti-programmed cell death 1 (anti-PD1) treatment has shown promising results in a recent phase II study. Although anti-PD1 treatment now offers higher response rates, the responses remain inconsistent and may lead to therapeutic impasses. Preclinical data have suggested synergy between anti-epidermal growth factor receptor (anti-EGFR) and immunotherapy. We report the case of a patient with metastatic cSCC that proved refractory first to anti-EGFR/carboplatin and then to immunotherapy, but who showed a complete and durable response with cetuximab/pembrolizumab combination. This response could reflect synergy of the two treatments.
Collapse
Affiliation(s)
- Candice Hober
- Service de Dermatologie, Hôpital C. Huriez, CHU de Lille,
Lille, Hauts-de-France, France
| | - Philippe Jamme
- Service de Dermatologie, Hôpital C. Huriez, CHU de Lille,
Lille, Hauts-de-France, France
| | - Eve Desmedt
- Service de Dermatologie, Hôpital C. Huriez, CHU de Lille,
Lille, Hauts-de-France, France
| | - Anna Greliak
- Service de Dermatologie, Hôpital C. Huriez, CHU de Lille,
Lille, Hauts-de-France, France
| | - Laurent Mortier
- Department of Dermatology, Hopital Claude Huriez, CHU of
Lille, rue Michel Polonowski, Lille, Hauts-de-France, 59000, France
| |
Collapse
|
4
|
Font G, Vuotto F, Desmedt E, Faure K, Mortier L. Risque infectieux sous inhibiteur du checkpoint : une série de 10 cas et mise en place d’une stratégie de prévention. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Hober C, Jamme P, Desmedt E, Greliak A, Mortier L. Réponse prolongée d’un carcinome épidermoïde cutané métastatique réfractaire avec l’association cétuximab/pembrolizumab. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Macaire C, Jamme P, Henri M, Robert C, Lesimple T, Thomas L, Machet L, Philippe S, Lebbe C, Dutriaux C, Grob JJ, Duhamel A, Labreuche J, Desmedt E, Templier C, Mirabel X, Reyns N, Le Rhun E, Mortier L. Traitement des patients atteints d’un mélanome métastatique cérébral par ipilimumab à haute dose et radiochirurgie : résultats à 5 ans. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Chambelland A, Koeppel MC, Desmedt E, Fongue J, Buono JP, Berbis P, Delaporte E. [Nodulocystic eruption induced by sorafenib]. Ann Dermatol Venereol 2019; 146:646-654. [PMID: 31362839 DOI: 10.1016/j.annder.2019.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2018] [Revised: 12/22/2018] [Accepted: 06/21/2019] [Indexed: 10/26/2022]
Abstract
INTRODUCTION Sorafenib is a multikinase inhibitor used in the treatment of hepatocellular carcinoma, advanced renal cell carcinoma, and differentiated thyroid carcinoma. Cutaneous adverse events are numerous and occur frequently. PATIENTS AND METHODS We present two cases of nodulocystic lesions associated with comedones in patients treated with sorafenib for hepatocellular carcinoma. In the first patient, a 64-year-old man, lesions appeared on the trunk one year after beginning sorafenib. Histopathological examination revealed a non-granulomatous, perivascular and perisudoral polymorphic cellular infiltrate associated with comedones and microcysts. These lesions progressed via inflammatory episodes interrupted by long periods of spontaneous remission without any specific treatment. In the second patient, a 53-year-old woman, a rash appeared on the buttocks three months after starting sorafenib and then spread to the lumbar region and thighs. Histopathological examination was consistent with granulomatous acne lesions. The initial treatment (oral tetracycline and zinc) given for 3 months proved ineffective. Patient follow-up over 3 years showed gradual regression without the appearance of any further lesions. DISCUSSION In the literature, several reports discuss acneiform rashes in patients treated with targeted therapy. In most cases, these lesions were papulopustular without retentional lesions. There are few reports of nodulocystic eruptions associated with comedones following sorafenib therapy. The mechanisms of emergence of these lesions seem to involve inhibition of the RAF pathway, C-KIT, and the PDGF signaling pathway.
Collapse
Affiliation(s)
- A Chambelland
- Service de dermatologie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France.
| | - M-C Koeppel
- Service de dermatologie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France
| | - E Desmedt
- Service de dermatologie, hôpital Claude-Huriez, CHRU, 59037 Lille, France
| | - J Fongue
- Service de dermatologie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France
| | - J-P Buono
- Service d'anatomie et cytologie pathologiques, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France
| | - P Berbis
- Service de dermatologie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France
| | - E Delaporte
- Service de dermatologie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France
| |
Collapse
|
8
|
Montaudié H, Le Duff F, Butori C, Hofman V, Fontas E, Roger-Cruzel C, Bahadoran P, Perrot JL, Desmedt E, Legoupil D, Passeron T, Lacour JP. Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit. J Am Acad Dermatol 2019; 82:731-733. [PMID: 31325551 DOI: 10.1016/j.jaad.2019.07.035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 07/10/2019] [Accepted: 07/11/2019] [Indexed: 10/26/2022]
Affiliation(s)
- Henri Montaudié
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France; Team 12, Centre Méditerranéen de Médecine Moléculaire, INSERM, U1065, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France.
| | - Florence Le Duff
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Catherine Butori
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Véronique Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Eric Fontas
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Délégation à la Recherche et à l'Innovation, Nice, France
| | - Coralie Roger-Cruzel
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Délégation à la Recherche et à l'Innovation, Nice, France
| | - Philippe Bahadoran
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France; Clinical Research Center Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Jean-Luc Perrot
- Department of Dermatology, University Hospital of Saint Etienne, Saint Etienne, France
| | - Eve Desmedt
- Department of Dermatology, University Hospital of Lille, INSERM U 1189, Lille, France
| | - Délphine Legoupil
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - Thierry Passeron
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France; Team 12, Centre Méditerranéen de Médecine Moléculaire, INSERM, U1065, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Jean-Philippe Lacour
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France; Team 12, Centre Méditerranéen de Médecine Moléculaire, INSERM, U1065, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
| |
Collapse
|
9
|
Montaudié H, Le Duff F, Butori C, Hofman V, Fontas E, Roger C, Bahadoran P, Perrot JL, Desmedt E, Legoupil D, Passeron T, Lacour JP. Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective and multicenter single-arm phase 2 trial. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e21051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21051 Background: Ingenol mebutate gel is indicated for the treatment of actinic keratoses. In vitro, it has been shown that ingenol mebutate can induce the apoptosis of melanoma cells, but robust clinical data are missing with only few case reports reported.The objectives of the current study was to assess the efficacy and safety of ingenol mebutate for the treatment of lentigo maligna (LM). Methods: We conducted a prospective, multicentre, and single-arm phase 2 trial (NCT02723721), from June 2016 to November 2017. This trial was planned according to Simon’s optimal two-stage design for a total sample size of 23 subjects. Adults with LM of the head were included. Ingenol mebutate gel 150 µg/g was applied daily for 3 consecutive days (one cycle). For patients having no remission or only partial remission at 2 months, a second cycle was done. Patients were evaluated 2 months after the (re)treatment and then every 3 months for 36 months if a complete response (CR) was obtained. The primary endpoint was the CR, defined as the complete clearing of the LM evaluated at 2 months clinically and histologically. Results: Twelve patients with a median age of 73 years were recruited. Only 2 achieved a CR; one patient relapsed during the first year following the treatment. Forty-seven adverse events related to ingenol mebutate were declared. Most were grade 3-4 (66%), but all were resolved without any sequelae. The mean maximum local skin reaction score was 12 (min: 3 – max: 22). These results should be interpreted with caution, because this study has limitations, such as the lack of a comparative arm and the heterogeneity of LM (size and localization). Conclusions: To our knowledge, we report the first prospective study evaluating the efficacy and safety of IM in patients with LM of the head. Unfortunately ingenol mebutate is not an effective treatment of LM in this indication at the concentration of 150 µg/g. Its use with a more intense regimen (more cycles and/or highest concentration (500 µg/g)) is also limited by a poor safety profile. Clinical trial information: NCT 02723721.
Collapse
Affiliation(s)
| | | | - Catherine Butori
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d'Azur, Nice, France
| | - Veronique Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d'Azur, Nice, France
| | - Eric Fontas
- Université Côte d’Azur, Centre Hospitalier Universitaire de Nice, Délégation à la Recherche et à l’Innovation, Nice, France
| | - Coralie Roger
- Université Côte d’Azur, Centre Hospitalier Universitaire de Nice, Délégation à la Recherche et à l’Innovation, Nice, France
| | | | - Jena-Luc Perrot
- Department of Dermatology, University Hospital of Saint Etienne, Saint Etienne, France
| | | | | | | | | |
Collapse
|
10
|
Guillot B, Dupuy A, Pracht M, Jeudy G, Hindie E, Desmedt E, Jouary T, Leccia MT. Actualisation des données concernant le mélanome stade III : nouvelles recommandations du groupe français de cancérologie cutanée. Ann Dermatol Venereol 2019; 146:204-214. [DOI: 10.1016/j.annder.2019.01.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 01/15/2019] [Indexed: 11/16/2022]
|
11
|
Mortier L, Bertrand N, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, Guillot B, Templier C, Desmedt E, Duhamel A, Depoortère C, Guerreschi P. Vismodégib en traitement néoadjuvant du carcinome basocellulaire localement avancé : premiers résultats de l’essai de phase 2 multicentrique VISMONEO. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.089] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Montaudié H, Le Duff F, Butori C, Hofman V, Fontas E, Roger C, Perrot JL, Desmedt E, Legoupil D, Passeron T, Lacour JP. Efficacité et tolérance du mébutate d’ingénol dans le mélanome de Dubreuilh in situ de la face : étude pilote, de phase II prospective et multicentrique indiquant aucun bénéfice. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Abi Rached H, Drouad M, Greliak A, Desmedt E, Templier C, Mortier L. Traitement néoadjuvant par chimiothérapie intra-lésionnelles par 5-fluorouracil de kératoacanthomes : à propos de 12 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Dubois M, Bataille B, Carlier D, Gras L, Tokarski M, Bonafos G, Demailly FX, Darloy F, Mortier L, Desmedt E. Radiothérapie de contact dans le traitement de carcinomes périoculaires : résultats carcinologiques et cosmétiques du centre Léonard-de-Vinci de Dechy. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Bataille B, Desmedt E, Bonafos G, Demailly F, Tokarski M, Carlier D, Gras L, Darloy F. Radiothérapie de contact pour les carcinomes péri-oculaires : résultats carcinologiques et cosmétiques du centre Léonard-de-Vinci de Dechy. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Girard E, Lacour A, Abi Rached H, Ramdane N, Templier C, Dziwniel V, Desmedt E, Le Rhun E, Mortier L. Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients. J Am Acad Dermatol 2018; 78:1213-1216.e2. [PMID: 29203435 DOI: 10.1016/j.jaad.2017.11.045] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 11/02/2017] [Accepted: 11/11/2017] [Indexed: 10/18/2022]
Affiliation(s)
- Edwina Girard
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France.
| | - Arnaud Lacour
- Center for Rare Neuromuscular Disorders, CHU Lille, Lille, France
| | - Henry Abi Rached
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
| | - Nassima Ramdane
- Public Health, Epidemiology, and Quality Management, University of Lille, CHU Lille, Lille, France
| | - Carole Templier
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
| | - Véronique Dziwniel
- Modern Languages Department, University of Lille, Centrale Lille, Villeneuve d'Ascq, France
| | - Eve Desmedt
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
| | - Emilie Le Rhun
- Neurooncology, Department of Neurosurgery, CHU Lille, France; Breast unit, Department of Medical Oncology, Oscar Lambret Center, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM) U1192, Laboratory of Proteomics, Inflammatory Response and Mass Spectrometry, Lille, France
| | - Laurent Mortier
- Department of Dermatology, University of Lille, INSERM U1189, CHU Lille, Lille, France
| |
Collapse
|
17
|
Mortier L, Jamme P, Lacour JP, Robert C, Lesimple T, Thomas L, Machet L, Saiag P, Lebbe C, Dutriaux C, Grob JJ, Duhamel A, Desmedt E, Templier C, Mirabel X, Reyns N, Le Rhun E. Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.9520] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Laurent Mortier
- Université Lille, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Philippe Jamme
- University of Lille, Dermatology department, CHU Lille, Inserm, U-1189, F-59000 Lille, Lille, France
| | | | | | - Thierry Lesimple
- Oncodermatology Unit, Eugene Marquis center CHU-CLCC, Rennes, France
| | - Luc Thomas
- Lyon University, Cancerology Institute of Lyon Civic Hospital, Cancer Research Centre of Lyon, Lyon, France, Pierre Benite, France
| | - Laurent Machet
- Dermatology department, CHRU, Inserm U-1253, University of Tours, France, Tours, France
| | - Philippe Saiag
- Dermatology department, CHU Ambroise Paré, AP-HP, Paris,, Boulogne-Billancourt, France
| | - Celeste Lebbe
- AP-HP Dermatology and CIC department, INSERM U976, Faculté Paris 7 Diderot, Saint-Louis hospital, AP-HP, Paris, France, Paris, France
| | - Caroline Dutriaux
- Dermatology and Pediatric dermatology department, Bordeaux hospital, Bordeaux, France, Bordeaux, France
| | - Jean-Jacques Grob
- Dermatology department, CHRU, AP-HM Hôpital de la Timone , Marseille France, Marseille, France
| | - Alain Duhamel
- Department of Biostatistics, University Lille Nord de France, CHRU de Lille, Lille, France
| | - Eve Desmedt
- Dermatology department, University of Lille, CHRU Lille, Lille, France
| | - Carole Templier
- University of Lille, Dermatology department, CHU Lille, Inserm, U-1189, F-59000 Lille, Lille, France
| | | | - Nicolas Reyns
- University of Lille, U-1192, F-59000 Lille, France; Inserm, U-1192, F-59000 Lille, France; CHU Lille, General and Stereotaxic Neurosurgery service, F-59000 Lille, France; Oscar Lambret Center, Medical Oncology Department, F-59000 Lille, Lille, France
| | - Emilie Le Rhun
- University of Lille, U-1192, F-59000 Lille, France; Inserm, U-1192, F-59000 Lille, France; CHU Lille, General and Stereotaxic Neurosurgery service, F-59000 Lille, France; Oscar Lambret Center, Medical Oncology Department, F-59000 Lille, Lille, France
| |
Collapse
|
18
|
Mortier L, Bertrand N, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, Guillot B, Templier C, Desmedt E, Duhamel A, Guerreschi P. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.9509] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Laurent Mortier
- Université Lille, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | | | - Nicole Basset-Seguin
- Dermatology Department, Hôpital Saint-Louis, Assistance-Publique-Hôpitaux de Paris, Paris, France
| | - Philippe Saiag
- Dermatology department, CHU Ambroise Paré, AP-HP, Paris,, Boulogne-Billancourt, France
| | - Alain Dupuy
- Dermatology department, Centre d'Oncodermatologie CLCC/CHU de Rennes, Rennes, France
| | - Sophie Dalac-Rat
- Dermatology department, CHU Dijon Bourgogne, CHU Le Bocage, Dijon, France
| | - Bernard Guillot
- Dermatology department, Universitary hospital of Montpellier, CHU Montpellier,, Montpellier, France
| | | | - Eve Desmedt
- Dermatology department, University of Lille, CHRU Lille, Lille, France
| | - Alain Duhamel
- Department of Biostatistics, University Lille Nord de France, CHRU de Lille, Lille, France
| | | |
Collapse
|
19
|
|
20
|
Maanaoui S, Scalbert C, Desmedt E, Templier C, Mortier L. Fasciite à éosinophiles invalidante sous pembrolizumab. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Oinino S, Rodrigues I, Boulanger T, Andre C, Bonneterre J, Zairi F, Mortier L, Desmedt E, Templier C, Le Rhun E. Prognosis of leptomeningeal metastases from melanoma: A case series of 28 patients. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e13550] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13550 Background: Leptomeningeal metastasis (LM) are reported in 5-25% of patients with melanoma. However, only very few large contemporary cohorts of melanoma patients with LM have been published. Methods: We report on a case series of 28 consecutive patients with LM from melanoma (BRAF mutated in 14 cases, of 19 tested) diagnosed between April 2007 and April 2016, and treated for LM using a combination of systemic treatment, intra-cerebrospinal fluid (CSF) therapy and radiotherapy according to prior treatments and the presentation of LM. Results: The median age at LM diagnosis was 49.5 years (range 27-73). Median ECOG-performance status was 2 (0-4). Concomitant brain metastases were present in all but 4 patients at LM diagnosis. LM was the first site of metastatic disease for only 2 patients. Median time from melanoma diagnosis to LM diagnosis was 0.33 years in patients with metastatic disease at melanoma diagnosis (4 patients) and 4.5 years in patients without metastatic disease at melanoma diagnosis (24 patients). First line treatment for LM was a combination of intra-CSF (liposomal cytarabine) and systemic treatments in 25 cases, and systemic treatment alone in 3 cases. Systemic treatments include chemotherapy (n = 18), targeted therapy (BRAF inhibitor n = 9; MEK inhibitor, n = 3) and immunotherapy (n = 4). No radiotherapy was performed. Ten patients received more than one line of treatment for LM. Median progression-free survival with first line treatment was 1.75 months. Responses or stabilization (for at least 2 months) were observed in only 7 patients. Median overall survival (OS) for the whole cohort was 3.08 months. Conclusions: The prognosis of patients with LM from melanoma remains poor. The role of new agents such as targeted therapies and immunotherapy for the treatment of LM is still not well defined. Adequate use of intrathecal chemotherapy, targeted therapy and immunotherapy could improve the survival of these patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Laurent Mortier
- Universite Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | | | | | | |
Collapse
|
22
|
Dezoteux F, Jacobsoone-Ulrich A, Mirabel X, Desmedt E, Lepesant P, Mortier L. Association radiothérapie et immunothérapie dans le traitement du mélanome localement avancé : un effet pseudo-abscopal ? Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
23
|
Marcant P, Lepesant P, Desmedt E, Mortier L. Psoriasis aggravé sous traitement par nivolumab dans le cadre d’un mélanome métastatique. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.564] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
|
25
|
Capelle C, Mambie A, Desmedt E, Morel T, Lemaire X. Un érythème polymorphe (EP) induit par le virus Epstein-Barr (EBV) avec complications multiples. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Rached H, Desmedt E, Templier C, Lepesant P, Mortier L. Variabilité intra-individuelle du profil mutationnel d’un mélanome métastatique. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
|
28
|
Capelle C, Fialek M, Lepesant P, Templier C, Desmedt E, Mortier L. Colite grave sous ipilimumab : une contre-indication aux anti-PD1 ? Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Leblais C, Lepesant P, Desmedt E, Mortier L. Une maladie bulleuse tardive. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
De Carvalho DG, Desmedt E, Lepesant P, Mortier L. Efficacité et tolérance d’un traitement intermittent par vismodégib (1 semaine sur 4) dans le traitement de carcinomes basocellulaires non résécables. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Fievet C, Desmedt E, Mortier L, Darloy F, Leroy T. Traitement des carcinomes basocellulaires du nez par radiothérapie de contact : expérience du centre Léonard de Vinci de Douai. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Faiz S, Magro L, Desmedt E, Herbaux C, Carpentier O, Mortier L. Réinjection de lymphocytes du donneur après allogreffe pour un mycosis fongoïde réfractaire. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Leroy T, Fievet C, Desmedt E, Carlier D, Gras L, Tokarski M, Darloy F. Contactothérapie dans le traitement des carcinomes basocellulaires du nez : expérience du centre Léonard-de-Vinci de Dechy. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Le Guern A, Becquart C, Desmedt E, Berthon C, Delaporte E, Staumont-Sallé D. Quand la toxidermie n’est pas limitée aux extrémités. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Girard E, Lacour A, Templier C, Desmedt E, Mortier L. Survenue de crampes sous vismodégib dans la prise en charge des carcinomes basocellulaires : étude prospective d’après l’expérience du CHRU de Lille chez 25 patients. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Le Guern A, Touzet L, Desmedt E, Mortier L. Limitation et arrêt des thérapeutiques dans le mélanome métastatique du sujet jeune. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
Affiliation(s)
- S Alkeraye
- Department of Dermatology, CHU Lille, Lille, France
| | - C Maire
- Department of Dermatology, CHU Lille, Lille, France
| | - E Desmedt
- Department of Dermatology, CHU Lille, Lille, France
| | - C Templier
- Department of Dermatology, CHU Lille, Lille, France
| | - L Mortier
- Department of Dermatology, CHU Lille, Lille, France
| |
Collapse
|
38
|
Le Guern A, Mortier L, Delaporte E, Desmedt E. Un effet indésirable inhabituel du sorafénib. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Sakji-Dupre L, Le Rhun E, Templier C, Desmedt E, Blanchet B, Mortier L. Concentrations du vémurafénib dans le liquide céphalo-rachidien (LCR) et le plasma : à propos de six patients. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
40
|
Dezoteux F, Templier C, Desmedt E, Maire C, Mortier L. Réintroduction d’inhibiteurs de BRAF dans le mélanome métastatique en situation d’impasse thérapeutique. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Vercambre-Darras S, Desmedt E, Maire C, Mortier L. [Melanomas that are difficult to diagnose]. Rev Prat 2014; 64:69-71. [PMID: 24649550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
42
|
Maire C, Vercambre-Darras S, Desmedt E. [Diagnosis of melanoma]. Rev Prat 2014; 64:61-68. [PMID: 24649548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Melanoma is a rare cancer but it is the cancer with the biggest increase of incidence, especially in caucasian populations. UV exposure and genetic predisposition are the two main risk factors. The diagnosis is often clinically suspected with the "ABCDE" rule. However, there are some diagnostic traps. Histological exam of the whole lesion will confirm diagnosis and guide the management. In case of localised melanoma, Breslow index is the best prognostic index. In case of metastatic melanoma, prognostic is dark. The AJCC classification stages patients in 4 groups according to their global survival.
Collapse
|
43
|
Chaddouki A, Templier C, Desmedt E, Alkeraye S, Daussay D, Martin-Delassalle E, Guerreschi P, Mortier L. [A "tattooed" lymph node mimicking metastatic melanoma]. Ann Dermatol Venereol 2013; 140:802-4. [PMID: 24315229 DOI: 10.1016/j.annder.2013.09.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2013] [Revised: 07/21/2013] [Accepted: 09/03/2013] [Indexed: 11/29/2022]
Affiliation(s)
- A Chaddouki
- Dermatologie, CHRU, 2, avenue Oscar-Lambret, 59000 Lille, France.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Becquart C, Ryckewaert G, Desmedt E, Defebvre L, Le Rhun E, Mortier L. [Limbic encephalitis: a new paraneoplastic auto-immune manifestation associated with metastatic melanoma?]. Ann Dermatol Venereol 2013; 140:278-81. [PMID: 23567229 DOI: 10.1016/j.annder.2013.01.424] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2012] [Revised: 12/01/2012] [Accepted: 01/11/2013] [Indexed: 11/18/2022]
Abstract
BACKGROUND Several studies indicate an association between immune-related manifestations and prolonged survival in metastatic melanoma. Limbic encephalitis driven by immune-mediated disorders may also be observed during the course of certain cancers. PATIENTS AND METHODS In November 2009, a 60-year-old woman followed up for metastatic melanoma since July 2005 developed rapidly progressive cognitive disorder. Clinical, biological, MRI and electroencephalogram abnormalities resulted in diagnosis of probably paraneoplastic limbic encephalitis in a context of immune-related manifestations although chemotoxicity could not be ruled out. Auto-immunity with hypothyroidism and thrombocytopenia were seen concomitantly. DISCUSSION To the best of our knowledge, this is the first reported case of probably paraneoplastic limbic encephalitis associated with melanoma, a new example of an immune-related condition associated with prolonged survival in metastatic melanoma.
Collapse
Affiliation(s)
- C Becquart
- Service de dermatologie, hôpital Claude-Huriez, rue Michel-Polonovski, 59037 Lille cedex, France.
| | | | | | | | | | | |
Collapse
|
45
|
Pape E, Desmedt E, Zairi F, Baranzelli MC, Dziwniel V, Dubois F, Bonneterre J, Mortier L, Le Rhun E. Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo 2012; 26:1079-1086. [PMID: 23160697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Melanoma has the highest rate of spread to the leptomeninges and the incidence of melanoma has been steadily rising. This article describes recent experience at the Lille University Hospital, between 2007 and 2011 and discusses the possibilities for treatment of leptomeningeal metastasis. PATIENTS AND METHODS Nine patients were diagnosed with leptomeningeal metastasis of melanoma. The standard criteria were used for the diagnosis. The treatment consisted of a combination of intrathecal chemotherapy, systemic chemotherapy and best supportive care. RESULTS The overall median survival from the time of leptomeningeal metastasis diagnosis was eight weeks (range=1-168 weeks). In two cases, the median overall survival was 104 weeks. For these patients, there was a clear benefit in intrathecal chemotherapy combined with systemic treatment. No complication was observed. CONCLUSION Despite a poor prognosis, treatment of melanoma leptomeningeal metastasis is needed in order to improve the quality of life, neurological progression-free survival and overall survival of patients.
Collapse
Affiliation(s)
- Emeline Pape
- Department of Dermatology, Huriez Hospital, Regional and University Hospital, Lille, France
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Chaddouki A, Desmedt E, Daussay D, Martin-Delasalle E, Mortier L. Un ganglion « tatoué » mimant une métastase de mélanome. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.09.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
47
|
Bertrand M, Desmedt E, Chaddouki A, Templier C, Staumont D, Mortier L. Nouvelle toxicité de l’ipilimumab : une éosinophilie majeure. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Bertrand ML, Desmedt E, Mirabel X, Mortier L. Carcinome de Merkel : carcinome radio-induit ? Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Desmedt E, Borne E, Lombardo A, Mirabel X, Martinot V, Darras-Vercambre S, Mortier L. [Detection of melanoma relapse: a retrospective study of 100 patients]. Ann Dermatol Venereol 2009; 136:767-71. [PMID: 19917428 DOI: 10.1016/j.annder.2009.09.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Accepted: 09/01/2009] [Indexed: 11/30/2022]
Abstract
BACKGROUND There is no international consensus on practical methods of monitoring melanoma following surgical removal of a primary tumour. The chief aim of such monitoring is to ensure detection of relapse where early diagnosis is crucial for survival (i.e. in-transit and lymph node metastases amenable to surgical removal) and the emergence of any first recurrence of primary melanoma. AIM The aim of our study was to identify the role of various agents and diagnostic tools both in first recurrence of primary melanoma and in clinical relapse of melanoma. PATIENTS AND METHODS This was a retrospective study covering all patients with in-transit or regional lymph node metastasis seen between January 2005 and December 2007. The type of recurrence and method of detection were studied. RESULTS Ninety-four patients presented recurrence, with 66% of relapses comprising regional lymph node metastasis and 34% consisting of in-transit metastases. Thirty-three percent of cases of recurrence were detected by patients themselves, 21% by our department, 22% by a private dermatologist, 18% by a radiologist and 6% by a general practitioner. Fifty-four percent of recurrences among patients aged under 50 years were self-detected compared to 18% among patients aged over 70 years. A second melanoma was detected in six patients. DISCUSSION This study underscores the great importance of self-examination in melanoma follow-up with over one third of recurrences being self-detected by patients. Self-examination was more effective for younger patients, emphasizing the need to increase awareness among older patients. This study also demonstrates the essential part played by dermatologists in terms of regular follow-up of melanoma.
Collapse
Affiliation(s)
- E Desmedt
- Clinique de dermatologie, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France
| | | | | | | | | | | | | |
Collapse
|
50
|
Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, Florin V, Martinot V, Penel N, Vercambre-Darras S, Mortier L. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 2009; 28:684-9. [DOI: 10.1007/s10637-009-9298-5] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2009] [Accepted: 07/28/2009] [Indexed: 11/28/2022]
|